ADDED VALUE OF 18FDG-PET-CT IN THE DIAGNOSIS OF INVASIVE FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS

ADDED VALUE OF 18FDG-PET-CT IN THE DIAGNOSIS OF INVASIVE FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS - Value of FDG-PET-CT in fungal infections in neutropenic patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35827

Enrollment

Registered

2011-07-28

Start date

2011-10-28

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive aspergillosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult patients (age > 18 years) with a hematologic disease who probably or possibly have an IFI. That means: * Prolonged (or expected prolonged) neutropenia (leukocyte count

Exclusion criteria

Exclusion criteria: * Patients with age

Design outcomes

Primary

Measure	Time frame
Has FDG-PET-CT additional value as imaging modality compared to the HR-CT thorax? Are their specific imaging characteristics found on FDG-PET-CT in relation to the 3 different described lesions found by HR-CT? Can FDG-PET-CT also provide information about the extension of the known lesions, i.e. is the halo sign on HR-CT involved in the infectious process or is it a sign of decreased perfusion due to infarction? * Can FDG-PET-CT detect enlarged and/or positive lymph nodes and what is the meaning of these lymph nodes in relation to prognosis or GM detection? * Is FDG-PET-CT able to find additional infectious lesions that are not visible on HR-CT of the thorax? Can FDG-PET-CT detect smaller lesions than HR-CT by its metabolic positivity and is there a relation between the total amount of metabolic positivity of lesions (mean SUV times area of positivity) and galactomannan positivity, which is a parameter of activity and/or invasiveness of aspergillosis? * Is FDG-PET-CT able to find additional infectious lesions that are not visible on HR-CT of the thorax because they are found outside the thorax? Sometimes IFI are found in the sinussen or gut or brain or combinations of these localisations.	—

Measure

Time frame

Has FDG-PET-CT additional value as imaging modality compared to the HR-CT thorax? Are their specific imaging characteristics found on FDG-PET-CT in relation to the 3 different described lesions found by HR-CT? Can FDG-PET-CT also provide information about the extension of the known lesions, i.e. is the halo sign on HR-CT involved in the infectious process or is it a sign of decreased perfusion due to infarction? * Can FDG-PET-CT detect enlarged and/or positive lymph nodes and what is the meaning of these lymph nodes in relation to prognosis or GM detection? * Is FDG-PET-CT able to find additional infectious lesions that are not visible on HR-CT of the thorax? Can FDG-PET-CT detect smaller lesions than HR-CT by its metabolic positivity and is there a relation between the total amount of metabolic positivity of lesions (mean SUV times area of positivity) and galactomannan positivity, which is a parameter of activity and/or invasiveness of aspergillosis? * Is FDG-PET-CT able to find additional infectious lesions that are not visible on HR-CT of the thorax because they are found outside the thorax? Sometimes IFI are found in the sinussen or gut or brain or combinations of these localisations.

—

Countries

Netherlands

Outcome results